A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension

Exclusion Criteria

• •1. Type 2 diabetes mellitus (T2DM) with a glycosylated hemoglobin (HbA1c) greater than (\>) 9 percent (%) (\>74.9 millimoles per mol \[mmol/mol\]) at the Screening Visit or history of diabetic ketoacidosis in the 6 months prior to the Screening Visit
• •2. Participants on a glucagon-like peptide-1 (GLP-1) agonist.
• •3. Any surgery for sleep apnea or major ear, nose or throat surgery, including tonsillectomy and adenoidectomy within 3 months prior to Screening, or planned during participation in the study or within 1 month of the last study visit.
• •4. Have diagnosis of central or mixed sleep apnea with % of mixed or central apneas/hypopneas ≥50%, or diagnosis of Cheyne Stokes Respiration
• •5. Diagnosis of Obesity Hypoventilation Syndrome or daytime hypercapnia
• •6. Use of bilevel positive airway pressure (BiPAP) therapy.
• •7. eGFR less than (\<) 45 milliliter per minute per 1.73 meter square (mL/min/1.73 m\^2) at Screening using serum creatinine or cystatin-C
• •8. History of clinically relevant medical, behavioral, or psychiatric disorder, other than OSA, that is associated with insomnia or excessive sleepiness
• •9. Diagnosed with Child-Pugh Class C
• •10. Participants who regularly use caffeine stimulants or participants who are unwilling to reduce intake to 300 mg per day (approximately 3 cups of coffee), for a period of at least 3 days prior to the Screening visit or a sleep study
• •11. Treatment with MRAs and/or epithelial sodium channel (ENaC) inhibitors within 1 month of the Screening Visit
• •12. Requirement for nocturnal use of supplemental oxygen
• •13. Women who are pregnant, plan to become pregnant, or are breastfeeding
• •14. Unstable or currently symptomatic cardiovascular disease or hospitalization in the 6 months prior to Screening
• •15. Previously diagnosed, recurrent orthostatic hypotension
• •16. Current night-shift worker or anticipated to become a night-shift worker for 3 days continuously during the duration of the study.